Skip to main content

Month: May 2020

Cue Biopharma Announces Strategic Research Collaboration with Dr. Michael Dustin and Oxford University

Collaboration to Study Immuno-STAT Biologics on T Cell Immunological Synapse Formation Using the IL-2-Based CUE-100 SeriesCAMBRIDGE, Mass., May 14, 2020 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today it has entered into a research collaboration agreement with Dr. Michael Dustin and the University of Oxford to determine the molecular mechanisms underlying the activity of its IL-2 based CUE-100 series Immuno-STAT™ (Selective Targeting and Alteration of T cells) Biologics.“Cue Biopharma is pleased to enter into this strategic collaboration with Dr. Dustin and the University of Oxford,” said Saso Cemerski, senior director of immuno-oncology discovery...

Continue reading

Histogen Publishes Preclinical Data on its HST 004 Spinal Disc Program

SAN DIEGO, May 14, 2020 (GLOBE NEWSWIRE) — Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today the publication of data on HST 004, its patented, naturally-derived material for spinal disc repair in the Journal of Medicine and Surgical Sciences.Histogen has developed a cell conditioned media (CCM) that is embryonic-like in composition and that has been shown to stimulate stem cells in vivo. The material expresses stem cell-associated proteins, including nodal, brachyury, nestin and Oct4, and has the potential to reduce inflammation and stimulate autologous intravertebral disc (IVD) cells, which can lead to the repair of IVD matrix.In a spinal disc study, HST 004 reversed inflammation and protease activity and stimulated aggrecan secretion...

Continue reading

Wolters Kluwer Appoints Leaders for its Health and Legal & Regulatory Divisions

Wolters Kluwer Appoints Leaders for its Health and Legal & Regulatory DivisionsMay 14, 2020 – Wolters Kluwer, a global provider of professional information, software solutions, and services, announces the appointments of Stacey Caywood as CEO of its Health division and Martin O’Malley as EVP & MD of its Legal & Regulatory division.Nancy McKinstry, CEO and Chairman of the Executive Board of Wolters Kluwer, commented: “We are very pleased to announce new positions for two of our most talented and experienced leaders. Stacey Caywood’s excellent leadership skills and strong track record of developing information and software portfolios will bring great benefits to the Health division and its global customer base. Martin O’Malley’s demonstrated success in leading businesses through change and in driving product innovation will...

Continue reading

SurveyMonkey’s Latest Microsoft Teams App Simplifies Employee Feedback

SAN MATEO, Calif., May 14, 2020 (GLOBE NEWSWIRE) — SurveyMonkey (Nasdaq: SVMK) today announced major new features and updates to its app integration with Microsoft Teams. These new features make it easier for team leaders and employees to stay connected, generate surveys, and collect feedback from one another as companies across the world are working from home. Microsoft Teams has over 75 million daily active users, with SurveyMonkey app usage up more than 90% since March.The latest updates empower customers with a broad range of features for Microsoft Teams that businesses can utilize every day, including designing surveys as well as collecting, analyzing, and acting on feedback. The expanded capabilities in Microsoft Teams will improve multiple key elements of its integration and enable organizations to generate feedback directly...

Continue reading

Constellation Pharmaceuticals Provides Update of Preliminary Data for CPI-0610 in Three EHA Abstracts

Continued high rate of SVR35 in 1L patients: 72% at 12 weeks and 67% at 24 weeksSVR35 responses and transfusion dependence conversion observed in 2L monotherapy patientsImprovement in bone marrow fibrosis seen across treatment armsAdditional data to be presented at EHA from ~50 1L and 70-80 2L patientsCAMBRIDGE, Mass., May 14, 2020 (GLOBE NEWSWIRE) — Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that three abstracts relating to the MANIFEST clinical trial of CPI-0610 in myelofibrosis were published online in association with the European Hematology Association (EHA) annual meeting. The abstracts include an analysis of data from 157 patients based on a data cutoff of January 9, 2020. An upcoming presentation of posters at EHA on June 12 will reflect an analysis of a larger patient population based on a later...

Continue reading

Live Ventures Announces Reopening of Vintage Stock Stores

LAS VEGAS, May 14, 2020 (GLOBE NEWSWIRE) — Live Ventures Incorporated (Nasdaq: LIVE), a diversified holding company, today provided a business update to its stakeholders and the communities in which its Vintage Stock stores operate.Vintage Stock began re-opening its stores on May 1 and, as of today, all but four of 62 stores have reopened and are operating in accordance with local guidelines.  To help ensure the health and safety of Vintage Stock’s team members and customers, the company has instituted numerous COVID-related safety measures, including requiring employees to wear face masks,  encouraging customers to wear face masks, installing sneeze guards at registers, enhancing cleaning of commonly touched surfaces, and requiring increased employee hand washing, just to name a few.“We are excited to be reopening our stores to...

Continue reading

Cellectar Granted Composition of Matter and Use Patent in Europe for CLR 131

FLORHAM PARK, N.J., May 14, 2020 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the European Patent Office has granted patent number EP 2440253 titled “Ether and Alkyl Phospholipid Compounds for Treating Cancer and Imaging and Detection of Cancer Stem Cells.” The patent provides composition of matter and use protection for the treatment and/or diagnosis of cancer and cancer stem cells for the company’s Phase 2 lead asset CLR 131 and the proprietary PLE analogs combined with I-125 (CLR 125).“Few drugs have shown the capacity to target and effectively treat highly resistant cancer stem cells. We believe CLR 131’s demonstrated ability to kill both conventional...

Continue reading

mophie debuts new powerstation wireless XL

ORANGE COUNTY, Calif., May 14, 2020 (GLOBE NEWSWIRE) — mophie, a ZAGG Brands (NASDAQ:ZAGG) company and the No. 1 external battery brand in the U.S.1, today announced the powerstation® wireless XL, available now. Featuring built-in Qi universal wireless input and output, a fast charge USB-C® input and output port, and a Lightning® input, the powerstation wireless XL is designed to conveniently and quickly charge iPhone® and other Apple devices on-the-go.A photo accompanying this announcement is available here, and a product feature video is available here.“Rounding out our new powerstation line, the powerstation wireless XL delivers the convenience of wireless charging and fast USB-C charging in one device to meet the portable power needs of Apple customers,” said Charlie Quong, vice president of product, power at ZAGG Brands. “With...

Continue reading

SANUWAVE Health to Deliver dermaPACE® to Patients in the Home Setting

SUWANEE, GA, May 14, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — SANUWAVE Health, Inc. (OTCQB: SNWV) is pleased to announce they will be offering dermaPACE® System solutions to treat patients in a home setting. SANUWAVE Health has quickly adapted to the changes occurring in the world of wound care.  The COVID-19 pandemic impacting the globe has changed, in the near term, and potentially the long term, the way wounds are being treated.  The experts are calling this paradigm shift “Wound Care Without Walls.”  The patients that would normally be treated on a weekly, or more often, basis in a wound clinic setting are now in need of evaluation and treatment in their home setting.  Center for Medicare and Medicaid Services (CMS) has moved quickly to allow reimbursement through use of certain waivers, allowing clinicians and home...

Continue reading

Kratos Mobile Laboratory Product Supporting COVID-19 Response Efforts

SAN DIEGO, May 14, 2020 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS), a leading National Security Solutions provider, announced today that its Mobile Laboratory Product, developed in part by the Kratos Command, Control, Communications, Computing, Combat & Intelligence, Surveillance and Reconnaissance (C5ISR) Division for the Department of Defense’s Analytical Laboratory System, Modified Work Order (ALS MWO) program, has been deployed as part of the National Guard’s efforts to combat COVID-19.The ALS program, run through the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), provides a common, mobile laboratory capability to DoD field analytic units across multiple domain spaces. The system provides on-site capability to detect and/or identify...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.